Bank of America started coverage on shares of Cytokinetics in a research report on Friday, February 17th.

Source: https://www.etfdailynews.com/2023/03/03/canada-pension-plan-investment-board-makes-new-349000-investment-in-cytokinetics-incorporated-nasdaqcytk/

Cytokinetics has a twelve month low of $30.66 and a twelve month high of $55.80.

Source: https://www.americanbankingnews.com/2023/08/06/cytokinetics-nasdaqcytk-stock-rating-reaffirmed-by-needham-company-llc.html

First Trust Advisors LP increased its holdings in shares of Cytokinetics, Incorporated () by 63.2% during the 4th quarter, reports.

Source: https://www.etfdailynews.com/2023/05/28/first-trust-advisors-lp-acquires-41947-shares-of-cytokinetics-incorporated-nasdaqcytk/

The study involved approximately 300 individuals with HCM, and those who received Cytokinetics drug, Alicante, experienced significant improvements in their peak oxygen uptake after 24 weeks of treatment.

Source: https://www.chiangraitimes.com/health/aficamten-a-heart-drug-by-cytokinetics/